Latest Insider Transactions at Larimar Therapeutics, Inc. (LRMR)
This section provides a real-time view of insider transactions for Larimar Therapeutics, Inc. (LRMR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Larimar Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Larimar Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 16
2024
|
Thomas Edward Hamilton Director |
BUY
Open market or private purchase
|
Direct |
57,208
+9.2%
|
$457,664
$8.74 P/Share
|
|
Feb 16
2024
|
James E Flynn Director |
BUY
Open market or private purchase
|
Indirect |
4,290,617
+21.03%
|
$34,324,936
$8.74 P/Share
|
|
Feb 14
2024
|
Frank E Thomas Director |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$22,000
$11.0 P/Share
|
|
Jan 17
2024
|
Carole Ben Maimon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,125
+16.57%
|
-
|
|
Jan 17
2024
|
Russell Clayton Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+50.0%
|
-
|
|
Jan 17
2024
|
Michael Celano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+17.83%
|
-
|
|
Jan 17
2024
|
Gopi Shankar Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+45.0%
|
-
|
|
Dec 07
2023
|
Gopi Shankar Chief Development Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$15,000
$3.73 P/Share
|
|
May 17
2023
|
Joseph Truitt Director |
BUY
Open market or private purchase
|
Direct |
2,750
+50.0%
|
$8,250
$3.73 P/Share
|
|
May 17
2023
|
Carole Ben Maimon President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+1.84%
|
$15,000
$3.7 P/Share
|
|
May 17
2023
|
Michael Celano Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.25%
|
$15,000
$3.73 P/Share
|
|
Jan 31
2023
|
Carole Ben Maimon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
205,000
+43.91%
|
-
|
|
Jan 31
2023
|
Michael Celano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
76,000
+41.36%
|
-
|
|
Sep 16
2022
|
Thomas Edward Hamilton Director |
BUY
Open market or private purchase
|
Direct |
317,460
+38.48%
|
$952,380
$3.15 P/Share
|
|
Sep 16
2022
|
James E Flynn Director |
BUY
Open market or private purchase
|
Indirect |
11,111,108
+40.28%
|
$33,333,324
$3.15 P/Share
|
|
Sep 16
2022
|
Michael Celano Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
31,746
+50.0%
|
$95,238
$3.15 P/Share
|
|
Sep 16
2022
|
Carole Ben Maimon President and CEO |
BUY
Open market or private purchase
|
Direct |
31,746
+35.84%
|
$95,238
$3.15 P/Share
|
|
Jun 30
2021
|
Thomas Edward Hamilton Director |
BUY
Open market or private purchase
|
Direct |
56,710
+22.97%
|
$453,680
$8.75 P/Share
|
|
Jun 30
2021
|
James E Flynn Director |
BUY
Open market or private purchase
|
Indirect |
685,710
+10.52%
|
$5,485,680
$8.75 P/Share
|